Voyageur Pharmaceuticals Expands Board with Wall Street Experts for U.S. Market Growth

The latest announcement is out from Voyageur Pharmaceuticals ( (TSE:VM) ).

Voyageur Pharmaceuticals Ltd. has expanded its board of directors by appointing two seasoned Wall Street executives, Jeffrey J. Kraws and Christopher A. Van Buren, to facilitate its expansion into the U.S. market. This strategic move is expected to attract significant American investment and support Voyageur’s growth in the diagnostic imaging sector. The new directors bring expertise in U.S. capital markets, IPO execution, and regulatory compliance, which will help Voyageur bridge its presence on the TSX Venture Exchange to the U.S. markets. This development aligns with Voyageur’s vision of becoming the first contrast media company with a secure supply chain of domestically produced products, ensuring long-term supply chain security for North American markets. The company is advancing its feasibility studies for the Frances Creek Barium Contrast project and the Oklahoma iodine project, positioning itself as the only vertically integrated radiology drug company globally.

More about Voyageur Pharmaceuticals

Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing pharmaceutical-grade barium and iodine for medical imaging contrast media. The company aims to vertically integrate the barium and iodine contrast markets and is working towards becoming a key player by producing its own barium and iodine. Voyageur is also exploring the development of new endo fullerene drugs and plans to partner with third-party GMP pharmaceutical manufacturers in Canada to validate its products globally. The company trades under the symbol VM on the TSX Venture Exchange.

Average Trading Volume: 103,509

Technical Sentiment Signal: Hold

Current Market Cap: C$23.56M

Find detailed analytics on VM stock on TipRanks’ Stock Analysis page.